Pharma News - Chemdiv

$MT-101 Granted Fast Track Designation by FDA for CD5+ Relapsed/Refractory Peripheral T-Cell Lymphoma$

MT-101 Granted Fast Track Designation by FDA for CD5+ Relapsed/Refractory Peripheral T-Cell Lymphoma

Patients with CD5-positive relapsed/refractory peripheral T-cell lymphoma may derive benefit from MT-101, which was granted fast track designation by the FDA.

ITM Gets Fast Track for Radiopharmaceutical Treatment for Neuroendocrine Tumors

ITM Isotope Technologies Munich has received FDA’s Fast Track designation for ITM-11, an investigational radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors. ...

Exploring novel mechanisms and therapeutic targets for acute myeloid leukemia

Patients with acute myeloid leukemia, the most common type of adult blood cancer, show large-scale genomic mutations and altered DNA folding patterns that could help identify potential therapeutic ...

Diet drug jab could help patients lose 10% of their weight in months by taking over body's appetite-regulating system, scientists say

An injection can help the overweight lose nearly a tenth of their body weight in just a few months, claim scientists. Researchers say the drug – yet to be named – hijacks a patient's appetite-r...

Cladribine Shows Efficacy, Tolerability Among Patients With MS Switching From Infusion DMTs

In a small real-world cohort, annualized relapse rates were reduced for patients with multiple sclerosis who switched to cladribine (Mavenclad; EMD Serono) from ocrelizumab (Ocrevus; Genentech), na...

Stevanato and DWK Life Sciences Enter Non-Exclusive Agreement

Stevanato Group S.p.A., a global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, and DWK Life Sciences, a global manufacturer...

GSK shelves arthritis blockbuster hope otilimab after lacklustre data

GSK has said it will not be able to move ahead with regulatory filings for otilimab as a treatment for rheumatoid arthritis (RA), after it failed to show the desired level of efficacy in two phase ...

NovAccess Global Gains Orphan Drug Status for Brain Cancer Drug Candidate

The FDA has granted an Orphan Drug designation to NovAccess Global’s for an investigational immunotherapy for aggressive brain cancers such as glioblastoma.

J&J nabs FDA okay for BCMA bispecific Tecvayli

Johnson & Johnson has secured another regulatory approval for its BCMAxCD3 bispecific antibody for multiple myeloma – Tecvayli – adding to the wide range of therapies available for the blo...

Vanda Pharmaceuticals Gains Orphan Drug Status for Investigational Cholera Drug

Vanda Pharmaceuticals’ VPO-227 has received FDA’s Orphan Drug designation for the treatment of patients with cholera.

Acumen Antibody Granted Fast Track Designation for Alzheimer's Disease

The FDA has granted Fast Track designation to Acumen Pharmaceuticals’ ACU193 for the treatment of patients with early Alzheimer’s disease.

New Agents, Clinical Research Promise More Personalized Treatment for Patients with Diabetic Kidney Disease, Type 2 Diabetes

SGLT-2 inhibitors, GLP-1 receptor agonists, and a non-steroidal mineralocorticoid receptor are all showing promise in the prevention and management of diabetic kidney disease. ...